Stereotactic Ablative Radiation Therapy in 3 Fractions Induces a Favorable Systemic Immune Cell Profiling in Prostate Cancer Patients.
Immunomonitoring
combined therapies
immunotherapy
peripheral immune cells
prostate cancer
radiotherapy
stereotactic body radiation therapy
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
entrez:
17
2
2023
pubmed:
18
2
2023
medline:
22
2
2023
Statut:
epublish
Résumé
The impact of radiotherapy (RT) on immune cell status in prostate cancer (PCa) is only partially determined. The aim of this study was to assess the effect of different RT strategies on peripheral B, T, and Natural killer (NK) lymphocytes at precise longitudinal time-points in PCa. 18 patients treated with stereotactic body radiation therapy (SBRT) (40 Gy/3FRX), definitive moderate-hypofractionation (62 Gy/20FRX), or post-operative conventional-fractionation RT (66-69 Gy/30FRX) were prospectively evaluated for the immune cell profile in terms of immune cell composition, differentiation stage, cytokine production and inhibitory receptor (IR) expression. The immune-monitoring of the 18 patients revealed that RT affects the balance of systemic immune cells, with the main differences observed between SBRT and conventionally fractionated RT. SBRT favorably impacts immune response in term of increased B cells, central-memory and effector-memory CD8
Identifiants
pubmed: 36798427
doi: 10.1080/2162402X.2023.2174721
pii: 2174721
pmc: PMC9928462
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2174721Informations de copyright
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
The authors report there are no competing interests to declare
Références
Nat Commun. 2021 Feb 10;12(1):935
pubmed: 33568675
Cancers (Basel). 2020 Jul 01;12(7):
pubmed: 32630247
Semin Immunol. 2019 Apr;42:101308
pubmed: 31604531
Clin Cancer Res. 2008 Jun 1;14(11):3254-61
pubmed: 18519750
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Front Oncol. 2022 Jul 07;12:888707
pubmed: 35875078
Pol Arch Intern Med. 2017 Apr 28;127(4):245-253
pubmed: 28420863
Nat Med. 2017 May;23(5):551-555
pubmed: 28346412
Cancer Res. 2020 Apr 15;80(8):1615-1623
pubmed: 32066566
Prostate Cancer Prostatic Dis. 2022 Jan 20;:
pubmed: 35058580
Pract Radiat Oncol. 2018 Nov - Dec;8(6):354-360
pubmed: 30322661
Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):684-692
pubmed: 35878715
J Radiat Res. 2021 Jan 1;62(1):110-118
pubmed: 33006364
Strahlenther Onkol. 2017 Aug;193(8):648-655
pubmed: 28500490
Eur Urol. 2022 Mar;81(3):253-262
pubmed: 34493414
Nat Commun. 2022 Jul 25;13(1):4298
pubmed: 35879302
Clin Cancer Res. 2021 Dec 1;27(23):6376-6383
pubmed: 34593526
Lancet. 2019 Aug 3;394(10196):385-395
pubmed: 31227373
Oncoimmunology. 2018 Aug 27;7(11):e1496881
pubmed: 30393582
Front Oncol. 2020 May 27;10:830
pubmed: 32670868
Lancet Oncol. 2022 Oct;23(10):1308-1320
pubmed: 36113498
J Circ Biomark. 2016 Mar 10;5:5
pubmed: 28936253
Cancer Cell. 2020 Oct 12;38(4):489-499.e3
pubmed: 32916128
Radiother Oncol. 2016 Jan;118(1):79-84
pubmed: 26702990
Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1259-1270
pubmed: 29891204
Oncoimmunology. 2017 Sep 14;7(1):e1364828
pubmed: 29296515
Int J Mol Sci. 2018 Dec 09;19(12):
pubmed: 30544863
Int J Radiat Oncol Biol Phys. 2021 Sep 1;111(1):93-100
pubmed: 33745951
Oncoimmunology. 2019 Feb 27;8(5):e1581546
pubmed: 31069143
Cancer Immunol Immunother. 2022 Mar;71(3):541-552
pubmed: 34269847
J Immunother Cancer. 2018 Dec 27;6(1):157
pubmed: 30587233
Sci Rep. 2017 Jul 7;7(1):4866
pubmed: 28687760
Cancers (Basel). 2021 May 02;13(9):
pubmed: 34063238
Transl Cancer Res. 2020 Jan;9(1):42-48
pubmed: 35117156
Blood. 1995 Apr 15;85(8):2124-31
pubmed: 7718883
J Hematol Oncol. 2020 Jun 29;13(1):83
pubmed: 32600443
J Immunol. 2010 Jul 15;185(2):1330-9
pubmed: 20548027
Nat Commun. 2022 Nov 16;13(1):7015
pubmed: 36385142
Clin Cancer Res. 2018 Nov 1;24(21):5368-5380
pubmed: 30042205
JAMA Netw Open. 2019 Feb 1;2(2):e188006
pubmed: 30735235
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):229-240
pubmed: 30205124
Cancer Lett. 2015 Nov 28;368(2):252-61
pubmed: 25754816
Int J Radiat Oncol Biol Phys. 2019 Jul 15;104(4):778-789
pubmed: 30959121